The role of human cytochrome P450 enzymes in metabolism of acrylamide in vitro

被引:13
|
作者
Kraus, Daria [1 ]
Rokitta, Dennis [1 ]
Fuhr, Uwe [1 ]
Tomalik-Scharte, Dorota [1 ]
机构
[1] Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany
关键词
Acrylamide metabolism; glycidamide; human CYP2E1 metabolism; DIETARY ACRYLAMIDE; MERCAPTURIC ACIDS; DIALLYL SULFIDE; RISK-ASSESSMENT; HUMAN URINE; GLYCIDAMIDE; CANCER; 2E1; DNA; INHIBITION;
D O I
10.3109/15376516.2012.759307
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Objective: Acrylamide (AA), a probable human carcinogen, is present in fried and baked starch-rich food. In vivo, the substance is partly biotransformed to glycidamide (GA), which may account for carcinogenic effects. Existing data suggest an important but not exclusive contribution of CYP2E1 to GA formation. The aim of this project was to derive respective enzyme kinetic parameters for CYP2E1 and to assess a possible role of other important human CYPs for this reaction in vitro. Methods: AA (0.2-20 mM) was incubated with human liver microsomes (HLM) and human cytochrome P450 enzymes (supersomes (TM)). GA was quantified by a specific LC-MS/MS method. Enzyme kinetic parameters were estimated assuming a single binding site. Furthermore, inhibition experiments were performed with diethyldithiocarbamate (DDC), a potent inhibitor of CYP2E1. Results: The mean +/- SD maximum formation rate (V-max) and Michaelis-Menten constant (K-m) for GA formation in HLM were 199 +/- 36 pmol GA/mg protein/min and 3.3 +/- 0.5 mM, respectively. In AA incubations with supersomes (TM), only for CYP2E1 measurable GA formation was detected in all tested AA concentrations (V-max and K-m were 5.4 nmol GA/nmol CYP2E1/min and 1.3 mM, respectively). Inhibition constant (IC50) of DDC was 3.1 +/- 0.5 mu M for HLM and 1.2 +/- 0.2 mu M for CYP2E1 supersomes (TM). Therefore, relevant participation of CYPs other than CYP2E1 in the metabolism of AA to GA in humans does not seem likely. Conclusion: Our results confirm the major role of CYP2E1 in GA formation from AA, albeit with low affinity and low capacity. Further studies are needed to identify other pathways of GA formation.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 50 条
  • [21] The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes
    Renwick, AG
    CLINICAL AND EXPERIMENTAL ALLERGY, 1999, 29 : 116 - 124
  • [22] In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol
    Oldham, HG
    Clarke, SE
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (08) : 970 - 977
  • [23] Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism
    Guengerich, F. Peter
    PHARMACOLOGICAL REVIEWS, 2024, 76 (06) : 1104 - 1132
  • [24] Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine
    Arbus, Christophe
    Benyamina, Amine
    Llorca, Pierre-Michel
    Bayle, Franck
    Bromet, Norbert
    Massiere, Frederic
    Garay, Ricardo P.
    Hameg, Ahceme
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 32 (4-5) : 357 - 366
  • [25] Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes
    Im-Soon Lee
    Donghak Kim
    Archives of Pharmacal Research, 2011, 34 : 1799 - 1816
  • [26] Polymorphic Metabolism by Functional Alterations of Human Cytochrome P450 Enzymes
    Lee, Im-Soon
    Kim, Donghak
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (11) : 1799 - 1816
  • [27] Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes
    Kim, KA
    Kim, MJ
    Park, JY
    Shon, JH
    Yoon, Y
    Lee, SS
    Liu, KH
    Chun, JH
    Hyun, MH
    Shin, JG
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (10) : 1227 - 1234
  • [28] Roles of Human Liver Cytochrome P450 Enzymes in Tenatoprazole Metabolism
    Le, Thien-Kim
    Park, Young Jin
    Cha, Gun Su
    Oktavia, Fikri A. R. Hardiyanti
    Kim, Dong Hyun
    Yun, Chul-Ho
    PHARMACEUTICS, 2023, 15 (01)
  • [29] Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol
    Hiratsuka, Masahiro
    Hinai, Yudai
    Sasaki, Takamitsu
    Konno, Yumiko
    Imagawa, Kenichi
    Ishikawa, Masaaki
    Mizugaki, Michinao
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) : 1730 - 1732
  • [30] Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
    Li, Jing
    Zhao, Ming
    He, Ping
    Hidalgo, Manuel
    Baker, Sharyn D.
    CLINICAL CANCER RESEARCH, 2007, 13 (12) : 3731 - 3737